Table 2.
Median titres of antibody preparations.
| Laboratory | sample numbers |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| 9 | 36 | 28 | 43 | 79 | 31 | 88 | 58 | 64 | |
| Neutralisation with wild type | |||||||||
| 2 (Zaire)a | < | < | < | < | 80 | < | < | < | < |
| 9 (Makona)a | < | < | 30 | < | < | < | < | 160 | < |
| 11a (Zaire)a | < | < | 45 | 27 | 181 | 91 | 64 | – | – |
| 12b (Makona)a | < | < | 30 | 20 | 160 | 20 | 20 | 20 | < |
| Pseudoneutralisation | |||||||||
| 6 (lentivirus) | < | Not reliable | |||||||
| 8 (EbolaVLP) | < | 24 | 66 | 106 | 129 | 22 | 22 | < | < |
| 15 (lentivirus) | < | 70 | 36,450 | 14,580 | 43,740 | 1620 | 540 | – | – |
| 17 (lentivirus) | < | 34 | 197 | 123 | 257 | 59 | 56 | < | < |
| 7 (non-replicating VSV) | < | < | 623 | 669 | 3395 | 1365 | 499 | 469 | 157 |
| 16b (replicating VSV) | < | < | 88 | 65 | 320 | 119 | 50 | – | – |
| ELISA (relative to 79) | |||||||||
| 1 | – | – | 0.49 | 0.63 | 1 | 0.85 | 0.8 | 0.69 | 0.3 |
| 3 | – | – | 0.36 | 0.46 | 1 | 0.77 | 0.45 | 0.45 | 0.14 |
| 4 | – | – | 0.45 | 0.78 | 1 | 0.68 | 0.52 | 0.65 | 0.14 |
| 5a | – | – | 0.29 | 0.5 | 1 | 1.33 | 0.65 | 1.06 | 0.26 |
| 5c | – | – | 0.81 | 0.07 | 1 | 0.21 | 0.27 | 0.41 | 0.12 |
| 10 | – | – | – | – | 1 | – | 0.16 | 0.24 | 0.08 |
| 12a | – | – | 0.41 | 0.59 | 1 | 1.01 | 0.69 | – | – |
| 13 | – | – | 0.88 | 0.61 | 1 | 0.04a | 0.34 | 0.81 | 0.7 |
| 16a | – | – | 0.61 | 0.68 | 1 | 0.63 | 1.43 | 3.1 | 0.51 |
| 16c | – | 1.19 | 0.27 | 0.22 | 1 | 0.03 | 0.51 | 0.26 | 0.08 |
| 16d | – | 8.81 | 0.43 | 0.5 | 1 | 0 | 0 | 0.37 | 0.51 |
| 16e | – | 12.81 | 0.66 | 0.74 | 1 | 0 | 0 | 0.6 | 0.69 |
Sample not assayed: –; antibody not detected:<.
Sample 9, 31, 88: human immunoglobulins from transchromosomal bovine.
Sample 36, 28, 43, 79: human samples from healthy donors (36) or convalescent patients.
Sample 58, 64: human samples from clinical trial.
Sample 79 was established as the first International reference reagent for Ebola antibodies by WHO in October 2015.
a
Strain used.